Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 782

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 782
---
,431,202 
  8,948,400 | ) |     | 2021 |   (583,443 
  3,548,582 
 20,337,839 
    (24,744 
  5,337,491 
     93,711 
  5,431,202 | ) 
 ) |
|:------------------------------------------------------------------------------|:----|:---------------------------------|-----------:|:--|:----|:-----|-----------:|:--|:----|:-----|-----------:|:--|
| Cash paid for interest                                                        |     | $                                |    145,153 |   |     | $    |     13,248 |   |     | $    |    339,932 |   |
| Issuance of note payable for prepaid insurance                                |     | $                                |            |   |     |      |    704,160 |   |     |      |          — |   |
| Deferred financing costs transferred to additional paid in capital            |     | $                                |          — |   |     | $    |          — |   |     | $    |    946,912 |   |
| Issuance of common shares to consultant for payment of expenses               |     | $                                |          — |   |     | $    |          — |   |     | $    |     50,000 |   |
| Issuance of common shares to Yorkville for partial payment of commitment fees |     | $                                |          — |   |     | $    |          — |   |     | $    |     59,455 |   |
| Debt discount on convertible loans                                            |     | $                                |          — |   |     | $    |     67,008 |   |     | $    |          — |   |
| Debt discount on convertible loan – related party                             |     | $                                |          — |   |     | $    |          — |   |     | $    |          — |   |

The accompanying notes are an integral part of these financial statements.

Annex F-122 NLS PHARMACEUTICS LTD.
NOTES TO THE FINANCIAL STATEMENTS Note 1 Background: NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (the “Company”) is an emerging biopharmaceutical company engaged in the discovery and development of life -impro